Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Lublin

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
JAMA Neurology|March 29, 2021
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical TrialLudwig Kappos, Robert J Fox, Michel Burcklen, et al.
Multiple Sclerosis and Related Disorders|July 23, 2025
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trialLudwig Kappos, Michel Burcklen, Daniele D'Ambrosio, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 28, 2017
Cerebellar lobule atrophy and disability in progressive MSSirio Cocozza, Maria Petracca, Enricomaria Mormina, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 24, 2018
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1aEva Havrdová, Douglas L Arnold, Amit Bar-Or, et al.
Lancet (London, England)|February 1, 2016
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialFred Lublin, David H Miller, Mark S Freedman, et al.
Medrxiv : the Preprint Server for Health Sciences|June 23, 2022
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapyIlana Katz Sand, Sacha Gnjatic, Florian Krammer, et al.
Multiple Sclerosis and Related Disorders|January 11, 2023
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapyIlana Katz Sand, Sacha Gnjatic, Florian Krammer, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L Hauser, Amit Bar-Or, Giancarlo Comi, et al.
Neurology|June 8, 2023
Polygenicity of Comorbid Depression in Multiple SclerosisKaarina Kowalec, Kathryn C Fitzgerald, Amber Salter, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalban, Stephen L Hauser, Ludwig Kappos, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
JAMA Neurology|March 29, 2021
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical TrialLudwig Kappos, Robert J Fox, Michel Burcklen, et al.
Multiple Sclerosis and Related Disorders|July 23, 2025
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trialLudwig Kappos, Michel Burcklen, Daniele D'Ambrosio, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 28, 2017
Cerebellar lobule atrophy and disability in progressive MSSirio Cocozza, Maria Petracca, Enricomaria Mormina, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 24, 2018
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1aEva Havrdová, Douglas L Arnold, Amit Bar-Or, et al.
Lancet (London, England)|February 1, 2016
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialFred Lublin, David H Miller, Mark S Freedman, et al.
Medrxiv : the Preprint Server for Health Sciences|June 23, 2022
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapyIlana Katz Sand, Sacha Gnjatic, Florian Krammer, et al.
Multiple Sclerosis and Related Disorders|January 11, 2023
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapyIlana Katz Sand, Sacha Gnjatic, Florian Krammer, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L Hauser, Amit Bar-Or, Giancarlo Comi, et al.
Neurology|June 8, 2023
Polygenicity of Comorbid Depression in Multiple SclerosisKaarina Kowalec, Kathryn C Fitzgerald, Amber Salter, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalban, Stephen L Hauser, Ludwig Kappos, et al.
Pageof 10